Lynk's Zemprocitinib Sustains 91.8% ACR20 Response Through Week 76
Hangzhou – October 29, 2026 -- Lynk Pharmaceuticals reported that its oral JAK1 inhibitor zemprocitinib sustained a 91.8% ACR20 response rate at Week 76 in rheumatoid arthritis patients who had failed or could not tolerate biologic therapy, with no new safety signals in the pivotal Phase III trial.
Trial met primary endpoint at Week 24 before long-term extension
The double-blind, placebo-controlled study randomized 430 patients with moderate-to-severe active RA and prior bDMARD inadequate response or intolerance; 429 received at least one dose. Patients received zemprocitinib 12 mg twice daily or placebo for 24 weeks. The trial met its primary ACR20 endpoint and key secondary endpoints versus placebo (p<0.0001). Patients then continued or switched to active treatment, with efficacy and safety tracked through Week 76 and a 4-week safety follow-up.